Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy.

Schiza N, Georgiou E, Kagiava A, Médard JJ, Richter J, Tryfonos C, Sargiannidou I, Heslegrave AJ, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Chrast R, Kleopa KA.

Brain. 2019 May 1;142(5):1227-1241. doi: 10.1093/brain/awz064.

2.

Regulatory role of oligodendrocyte gap junctions in inflammatory demyelination.

Papaneophytou CP, Georgiou E, Karaiskos C, Sargiannidou I, Markoullis K, Freidin MM, Abrams CK, Kleopa KA.

Glia. 2018 Dec;66(12):2589-2603. doi: 10.1002/glia.23513. Epub 2018 Oct 16.

3.

Intrathecal Delivery of Viral Vectors for Gene Therapy.

Kagiava A, Kleopa KA.

Methods Mol Biol. 2018;1791:277-285. doi: 10.1007/978-1-4939-7862-5_22.

PMID:
30006718
4.

Intrathecal gene therapy in mouse models expressing CMT1X mutations.

Kagiava A, Karaiskos C, Richter J, Tryfonos C, Lapathitis G, Sargiannidou I, Christodoulou C, Kleopa KA.

Hum Mol Genet. 2018 Apr 15;27(8):1460-1473. doi: 10.1093/hmg/ddy056.

PMID:
29462293
5.

Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN.

Christou YP, Tanteles GA, Kkolou E, Ormiston A, Konstantopoulos K, Beconi M, Marshall RD, Plotkin H, Kleopa KA.

Case Rep Neurol Med. 2017;2017:3247034. doi: 10.1155/2017/3247034. Epub 2017 Apr 16.

6.

Epidemiology of Amyotrophic Lateral Sclerosis in the Republic of Cyprus: A 25-Year Retrospective Study.

Demetriou CA, Hadjivasiliou PM, Kleopa KA, Christou YP, Leonidou E, Kyriakides T, Zamba-Papanicolaou E.

Neuroepidemiology. 2017;48(1-2):79-85. doi: 10.1159/000477126. Epub 2017 May 20.

PMID:
28528330
7.

A quantitative method for the assessment of dysarthrophonia in myasthenia gravis.

Konstantopoulos K, Christou YP, Vogazianos P, Zamba-Papanicolaou E, Kleopa KA.

J Neurol Sci. 2017 Jun 15;377:42-46. doi: 10.1016/j.jns.2017.03.045. Epub 2017 Mar 31.

PMID:
28477705
8.

Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X.

Kyriakoudi S, Sargiannidou I, Kagiava A, Olympiou M, Kleopa KA.

Hum Mol Genet. 2017 May 1;26(9):1622-1633. doi: 10.1093/hmg/ddx064.

PMID:
28334782
9.

Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model.

Georgiou E, Sidiropoulou K, Richter J, Papaneophytou C, Sargiannidou I, Kagiava A, von Jonquieres G, Christodoulou C, Klugmann M, Kleopa KA.

Brain. 2017 Mar 1;140(3):599-616. doi: 10.1093/brain/aww351.

10.

Loss of Coupling Distinguishes GJB1 Mutations Associated with CNS Manifestations of CMT1X from Those Without CNS Manifestations.

Abrams CK, Goman M, Wong S, Scherer SS, Kleopa KA, Peinado A, Freidin MM.

Sci Rep. 2017 Jan 10;7:40166. doi: 10.1038/srep40166.

11.

Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease.

Olympiou M, Sargiannidou I, Markoullis K, Karaiskos C, Kagiava A, Kyriakoudi S, Abrams CK, Kleopa KA.

Acta Neuropathol Commun. 2016 Sep 1;4(1):95. doi: 10.1186/s40478-016-0369-5.

12.

Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy.

Kagiava A, Sargiannidou I, Theophilidis G, Karaiskos C, Richter J, Bashiardes S, Schiza N, Nearchou M, Christodoulou C, Scherer SS, Kleopa KA.

Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2421-9. doi: 10.1073/pnas.1522202113. Epub 2016 Mar 28.

13.

Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen.

Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Gilhus NE, Casasnovas Pons C, Pitha J, Jakubíkova M, Hanisch F, Bogomolovas J, Labeit D, Labeit S, Tzartos SJ.

J Neuroimmunol. 2016 Mar 15;292:108-15. doi: 10.1016/j.jneuroim.2016.01.018. Epub 2016 Jan 27.

PMID:
26943968
14.

In the Clinic. Carpal Tunnel Syndrome.

Kleopa KA.

Ann Intern Med. 2015 Sep 1;163(5):ITC1. doi: 10.7326/AITC201509010. Review.

PMID:
26322711
15.

Differential modulation of the juxtaparanodal complex in Multiple Sclerosis.

Kastriti ME, Sargiannidou I, Kleopa KA, Karagogeos D.

Mol Cell Neurosci. 2015 Jul;67:93-103. doi: 10.1016/j.mcn.2015.06.005. Epub 2015 Jun 10.

PMID:
26070930
16.

Oxaliplatin-induced neurotoxicity is mediated through gap junction channels and hemichannels and can be prevented by octanol.

Kagiava A, Theophilidis G, Sargiannidou I, Kyriacou K, Kleopa KA.

Neuropharmacology. 2015 Oct;97:289-305. doi: 10.1016/j.neuropharm.2015.05.021. Epub 2015 Jun 1.

PMID:
26044641
17.

MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study.

Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Casasnovas Pons C, Pitha J, Jakubíkova M, Hanisch F, Tzartos SJ.

J Neuroimmunol. 2015 Jul 15;284:10-7. doi: 10.1016/j.jneuroim.2015.04.015. Epub 2015 Apr 27.

PMID:
26025053
18.

Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease.

Sargiannidou I, Kagiava A, Bashiardes S, Richter J, Christodoulou C, Scherer SS, Kleopa KA.

Ann Neurol. 2015 Aug;78(2):303-16. doi: 10.1002/ana.24441. Epub 2015 Jun 30.

PMID:
26010264
19.

Connexin43 and connexin47 alterations after neural precursor cells transplantation in experimental autoimmune encephalomyelitis.

Theotokis P, Kleopa KA, Touloumi O, Lagoudaki R, Lourbopoulos A, Nousiopoulou E, Kesidou E, Poulatsidou KN, Dardiotis E, Hadjigeorgiou G, Karacostas D, Cifuentes-Diaz C, Irinopoulou T, Grigoriadis N.

Glia. 2015 Oct;63(10):1772-83. doi: 10.1002/glia.22843. Epub 2015 Apr 27.

PMID:
25914045
20.

A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32.

Sargiannidou I, Kim GH, Kyriakoudi S, Eun BL, Kleopa KA.

Neurogenetics. 2015 Jul;16(3):193-200. doi: 10.1007/s10048-015-0442-4. Epub 2015 Mar 15.

PMID:
25771809
21.

Novel GLI3 mutation in a Greek-Cypriot patient with Greig cephalopolysyndactyly syndrome.

Tanteles GA, Michaelidou S, Loukianou E, Christophidou-Anastasiadou V, Kleopa KA.

Clin Dysmorphol. 2015 Jul;24(3):102-5. doi: 10.1097/MCD.0000000000000074.

PMID:
25714367
22.

Transgenic replacement of Cx32 in gap junction-deficient oligodendrocytes rescues the phenotype of a hypomyelinating leukodystrophy model.

Schiza N, Sargiannidou I, Kagiava A, Karaiskos C, Nearchou M, Kleopa KA.

Hum Mol Genet. 2015 Apr 1;24(7):2049-64. doi: 10.1093/hmg/ddu725. Epub 2014 Dec 18.

PMID:
25524707
23.

Connexins, gap junctions and peripheral neuropathy.

Kleopa KA, Sargiannidou I.

Neurosci Lett. 2015 Jun 2;596:27-32. doi: 10.1016/j.neulet.2014.10.033. Epub 2014 Oct 24. Review.

PMID:
25449862
24.

Gene delivery targeted to oligodendrocytes using a lentiviral vector.

Kagiava A, Sargiannidou I, Bashiardes S, Richter J, Schiza N, Christodoulou C, Gritti A, Kleopa KA.

J Gene Med. 2014 Nov-Dec;16(11-12):364-73. doi: 10.1002/jgm.2813.

PMID:
25394283
25.

Oligodendrocyte gap junction loss and disconnection from reactive astrocytes in multiple sclerosis gray matter.

Markoullis K, Sargiannidou I, Schiza N, Roncaroli F, Reynolds R, Kleopa KA.

J Neuropathol Exp Neurol. 2014 Sep;73(9):865-79. doi: 10.1097/NEN.0000000000000106.

PMID:
25101702
26.

Novel homozygous PANK2 mutation causing atypical pantothenate kinase-associated neurodegeneration (PKAN) in a Cypriot family.

Tanteles GA, Spanou-Aristidou E, Antoniou C, Christophidou-Anastasiadou V, Kleopa KA.

J Neurol Sci. 2014 May 15;340(1-2):233-6. doi: 10.1016/j.jns.2014.03.001. Epub 2014 Mar 11.

PMID:
24655737
27.

A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.

Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Frenkian Cuvelier M, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ.

J Autoimmun. 2014 Aug;52:139-45. doi: 10.1016/j.jaut.2013.12.004. Epub 2013 Dec 24.

PMID:
24373505
28.

Alterations of juxtaparanodal domains in two rodent models of CNS demyelination.

Zoupi L, Markoullis K, Kleopa KA, Karagogeos D.

Glia. 2013 Aug;61(8):1236-49. doi: 10.1002/glia.22511. Epub 2013 Jul 5.

PMID:
23828637
29.

X-linked Charcot-Marie-Tooth disease.

Scherer SS, Kleopa KA.

J Peripher Nerv Syst. 2012 Dec;17 Suppl 3:9-13. doi: 10.1111/j.1529-8027.2012.00424.x. Review.

30.

Investigation of SCA10 in the Cypriot population: further exclusion of SCA dynamic repeat mutations.

Votsi C, Zamba-Papanicolaou E, Georghiou A, Kyriakides T, Papacostas S, Kleopa KA, Pantzaris M, Christodoulou K.

J Neurol Sci. 2012 Dec 15;323(1-2):154-7. doi: 10.1016/j.jns.2012.09.006. Epub 2012 Sep 29.

PMID:
23026538
31.

How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?

Kleopa KA, Abrams CK, Scherer SS.

Brain Res. 2012 Dec 3;1487:198-205. doi: 10.1016/j.brainres.2012.03.068. Epub 2012 Jul 6. Review.

32.

Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter.

Markoullis K, Sargiannidou I, Schiza N, Hadjisavvas A, Roncaroli F, Reynolds R, Kleopa KA.

Acta Neuropathol. 2012 Jun;123(6):873-86. doi: 10.1007/s00401-012-0978-4. Epub 2012 Apr 7.

PMID:
22484441
33.

Morvan syndrome: clinical and serological observations in 29 cases.

Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, Zuliani L, Watanabe O, Lang B, Buckley C, Vincent A.

Ann Neurol. 2012 Aug;72(2):241-55. doi: 10.1002/ana.23577. Epub 2012 Apr 4.

PMID:
22473710
34.

Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis.

Markoullis K, Sargiannidou I, Gardner C, Hadjisavvas A, Reynolds R, Kleopa KA.

Glia. 2012 Jul;60(7):1053-66. doi: 10.1002/glia.22334. Epub 2012 Mar 27.

PMID:
22461072
35.

Autoimmune channelopathies of the nervous system.

Kleopa KA.

Curr Neuropharmacol. 2011 Sep;9(3):458-67. doi: 10.2174/157015911796557966.

36.

The role of gap junctions in Charcot-Marie-Tooth disease.

Kleopa KA.

J Neurosci. 2011 Dec 7;31(49):17753-60. doi: 10.1523/JNEUROSCI.4824-11.2011. No abstract available.

37.

Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex.

Loukaides P, Schiza N, Pettingill P, Palazis L, Vounou E, Vincent A, Kleopa KA.

J Neurol Sci. 2012 Jan 15;312(1-2):52-6. doi: 10.1016/j.jns.2011.08.024. Epub 2011 Sep 8.

PMID:
21906755
38.

Gap junction disorders of myelinating cells.

Kleopa KA, Orthmann-Murphy J, Sargiannidou I.

Rev Neurosci. 2010;21(5):397-419. Review.

PMID:
21280457
39.

Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy.

Vavlitou N, Sargiannidou I, Markoullis K, Kyriacou K, Scherer SS, Kleopa KA.

J Neuropathol Exp Neurol. 2010 Sep;69(9):945-58. doi: 10.1097/NEN.0b013e3181efa658.

40.

Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia.

Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A.

Brain. 2010 Sep;133(9):2734-48. doi: 10.1093/brain/awq213. Epub 2010 Jul 27.

41.

Molecular mechanisms of gap junction mutations in myelinating cells.

Sargiannidou I, Markoullis K, Kleopa KA.

Histol Histopathol. 2010 Sep;25(9):1191-206. doi: 10.14670/HH-25.1191. Review.

PMID:
20607661
42.

Charcot-Marie-Tooth disease in Cyprus: epidemiological, clinical and genetic characteristics.

Nicolaou P, Zamba-Papanicolaou E, Koutsou P, Kleopa KA, Georghiou A, Hadjigeorgiou G, Papadimitriou A, Kyriakides T, Christodoulou K.

Neuroepidemiology. 2010;35(3):171-7. doi: 10.1159/000314351. Epub 2010 Jun 23.

PMID:
20571287
43.

Human GLUD2 glutamate dehydrogenase is expressed in neural and testicular supporting cells.

Spanaki C, Zaganas I, Kleopa KA, Plaitakis A.

J Biol Chem. 2010 May 28;285(22):16748-56. doi: 10.1074/jbc.M109.092999. Epub 2010 Mar 1.

44.

Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects.

Sargiannidou I, Vavlitou N, Aristodemou S, Hadjisavvas A, Kyriacou K, Scherer SS, Kleopa KA.

J Neurosci. 2009 Apr 15;29(15):4736-49. doi: 10.1523/JNEUROSCI.0325-09.2009.

45.

Acute cervical radiculopathies in spontaneous intracranial hypotension.

Kleopa KA, Natsiopoulos K.

J Neurol. 2009 Mar;256(3):499-501. doi: 10.1007/s00415-009-0095-z. Epub 2009 Mar 13. No abstract available.

PMID:
19277760
46.

A novel ALS2 splice-site mutation in a Cypriot juvenile-onset primary lateral sclerosis family.

Mintchev N, Zamba-Papanicolaou E, Kleopa KA, Christodoulou K.

Neurology. 2009 Jan 6;72(1):28-32. doi: 10.1212/01.wnl.0000338530.77394.60.

PMID:
19122027
47.

Impairment of learning and memory in TAG-1 deficient mice associated with shorter CNS internodes and disrupted juxtaparanodes.

Savvaki M, Panagiotaropoulos T, Stamatakis A, Sargiannidou I, Karatzioula P, Watanabe K, Stylianopoulou F, Karagogeos D, Kleopa KA.

Mol Cell Neurosci. 2008 Nov;39(3):478-90. doi: 10.1016/j.mcn.2008.07.025. Epub 2008 Aug 9.

PMID:
18760366
48.

Human oligodendrocytes express Cx31.3: function and interactions with Cx32 mutants.

Sargiannidou I, Ahn M, Enriquez AD, Peinado A, Reynolds R, Abrams C, Scherer SS, Kleopa KA.

Neurobiol Dis. 2008 May;30(2):221-33. doi: 10.1016/j.nbd.2008.01.009. Epub 2008 Feb 15.

49.

Autoimmune channelopathies and related neurological disorders.

Vincent A, Lang B, Kleopa KA.

Neuron. 2006 Oct 5;52(1):123-38. Review.

50.

Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes.

Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J.

J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):381-5. Epub 2006 Sep 15.

Supplemental Content

Loading ...
Support Center